VSVolodymyr Shablii

Volodymyr Shablii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Volodymyr Shablii has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Tetiana Bukreieva

    Laboratory of Biosynthesis of Nucleic Acids, Department of Functional Genomics, Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Kyiv 03143, Ukraine

    2 shared publications
  • Alina Ustymenko

    Laboratory of Pathophysiology and Immunology , Chebotarev State Institute of Gerontology of the National Academy of Medical Sciences of Ukraine , Kyiv , Ukraine

    1 shared publication
  • Alyona Vega

    Department of Infectious Diseases, Shupyk National Healthcare University of Ukraine, Kyiv 04112, Ukraine

    1 shared publication
  • Alyona Vega

    Department of Infectious Diseases, Shupyk National Healthcare University of Ukraine, 04112 Kyiv, Ukraine

    1 shared publication
  • Galyna Lobyntseva

    Placenta Stem Cell Laboratory, Cryobank, Institute of Cell Therapy, Kyiv 03126, Ukraine

    1 shared publication
  • Galyna Lobyntseva

    Placenta Stem Cell Laboratory, Cryobank, Institute of Cell Therapy, 03035 Kyiv, Ukraine

    1 shared publication

Latest Publications

  • Open Access

    Dynamic changes in radiological parameters, immune cells, selected miRNAs, and cytokine levels in peripheral blood of patients with severe COVID‑19

    by Tetiana Bukreieva, Vitalii Kyryk, Viktoriia Nikulina, Hanna Svitina, Alyona Vega, Oleksii Chybisov, Iuliia Shablii, Oksana Mankovska, Galyna Lobyntseva, Petro Nemtinov, et al.

    The present study aimed to investigate the dynamic changes in peripheral blood leucocyte subpopulations, cytokine and miRNA levels, and changes in computed tomography (CT) scores in patients with severe coronavirus disease 2019 (COVID‑19) (n=14) and age‑matched non‑COVID‑19 volunteers (n=17), which were included as a reference control group. All data were collected on the day of patient admission (day 0) and on the 7th, 14th and 28th days of follow‑up while CT of the lungs was performed on weeks 2, 8, 24 and 48. On day 0, lymphopenia and leucopenia were detected in most patients with COVID‑19, as well as an increase in the percentage of banded neutrophils, B cells, and CD4+ Treg cells, and a decrease in the content of PD‑1low T cells, classical, plasmacytoid, and regulatory dendritic cells. On day 7, the percentage of T and natural killer cells decreased with a concurrent increase in B cells, but returned to the initial level after treatment discharge. The content of different T and dendritic cell subsets among CD45+ cells increased during two weeks and remained elevated, suggesting the activation of an adaptive immune response. The increase of PD‑1‑positive subpopulations of T and non‑T cells and regulatory CD4 T cells in patients with COVID‑19 during the observation period suggests the development of an inflammation control mechanism. The levels of interferon γ‑induced protein 10 (IP‑10), tumor necrosis factor‑α (TNF‑α) and interleukin (IL)‑6 decreased on day 7, but increased again on days 14 and 28. C‑reactive protein and granulocyte colony‑stimulating factor (G‑CSF) levels decreased gradually throughout the observation period. The relative expression levels of microRNA (miR)‑21‑5p, miR‑221‑3p, miR‑27a‑3p, miR‑146a‑5p, miR‑133a‑3p, and miR‑126‑3p were significantly higher at the beginning of hospitalization compared to non‑COVID‑19 volunteers. The plasma levels of all miRs, except for miR‑126‑3p, normalized within one week of treatment. At week 48, CT scores were most prominently correlated with the content of lymphocytes, senescent memory T cells, CD127+ T cells and CD57+ T cells, and increased concentrations of G‑CSF, IP‑10, and macrophage inflammatory protein‑1α.


  • Open Access

    Treatment of Acute Respiratory Distress Syndrome Caused by COVID-19 with Human Umbilical Cord Mesenchymal Stem Cells

    by Tetiana Bukreieva, Hanna Svitina, Viktoriia Nikulina, Alyona Vega, Oleksii Chybisov, Iuliia Shablii, Alina Ustymenko, Petro Nemtinov, Galyna Lobyntseva, Inessa Skrypkina, et al.

    This study aimed to identify the impact of mesenchymal stem cell transplantation on the safety and clinical outcomes of patients with severe COVID-19. This research focused on how lung functional status, miRNA, and cytokine levels changed following mesenchymal stem cell transplantation in patients with severe COVID-19 pneumonia and their correlation with fibrotic changes in the lung. This study involved 15 patients following conventional anti-viral treatment (Control group) and 13 patients after three consecutive doses of combined treatment with MSC transplantation (MCS group). ELISA was used to measure cytokine levels, real-time qPCR for miRNA expression, and lung computed tomography (CT) imaging to grade fibrosis. Data were collected on the day of patient admission (day 0) and on the 7th, 14th, and 28th days of follow-up. A lung CT assay was performed on weeks 2, 8, 24, and 48 after the beginning of hospitalization. The relationship between levels of biomarkers in peripheral blood and lung function parameters was investigated using correlation analysis. We confirmed that triple MSC transplantation in individuals with severe COVID-19 was safe and did not cause severe adverse reactions. The total score of lung CT between patients from the Control and MSC groups did not differ significantly on weeks 2, 8, and 24 after the beginning of hospitalization. However, on week 48, the CT total score was 12 times lower in patients in the MSC group (p ≤ 0.05) compared to the Control group. In the MSC group, this parameter gradually decreased from week 2 to week 48 of observation, whereas in the Control group, a significant drop was observed up to week 24 and remained unchanged afterward. In our study, MSC therapy improved lymphocyte recovery. The percentage of banded neutrophils in the MSC group was significantly lower in comparison with control patients on day 14. Inflammatory markers such as ESR and CRP decreased more rapidly in the MSC group in comparison to the Control group. The plasma levels of surfactant D, a marker of alveocyte type II damage, decreased after MSC transplantation for four weeks in contrast to patients in the Control group, in whom slight elevations were observed. We first showed that MSC transplantation in severe COVID-19 patients led to the elevation of the plasma levels of IP-10, MIP-1α, G-CSF, and IL-10. However, the plasma levels of inflammatory markers such as IL-6, MCP-1, and RAGE did not differ between groups. MSC transplantation had no impact on the relative expression levels of miR-146a, miR-27a, miR-126, miR-221, miR-21, miR-133, miR-92a-3p, miR-124, and miR-424. In vitro, UC-MSC exhibited an immunomodulatory impact on PBMC, increasing neutrophil activation, phagocytosis, and leukocyte movement, activating early T cell markers, and decreasing effector and senescent effector T cell maturation.